Pehea e hoʻohana ai iā Fenofibrate?

ʻO Fenofibrate kahi lipid hōʻemi haʻahaʻa i hoʻohanaʻia e mālama i ka hypercholesterolemia a me ka hyperlipidemia i hui ʻia. Hoʻokomo ʻia nā hopena i ka hoʻōla ʻana o nā mea hoʻokomo aku ʻo PPARα. Lawe ʻia ka lāʻau lāʻau hoʻokahi i ka lā me ka meaʻai. ʻO ka hopena maʻamau e pili ana i ka maʻi poʻo a me ka indigestion. Hiki i ka Fenofibrate ke hana i ka ʻili o ka ʻili i ka lā.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

Loaʻa ka Fenofibrate i ke ʻano o kahi paukū keʻokeʻo keʻokeʻo, kahi hoʻohālikelike ʻia i ka wai. Hoʻomili ka prodrug i ke kino i ka hoʻolaʻa fenofibric ikaika.

I kēia manawa (2018), hoʻohana pinepine ʻia nā micofized fenofibrate.

ʻAʻohe! Ua hoʻomohala ʻia ka lāʻau lapaʻau e ka hui lāʻau lapaʻau ʻo Fournier Pharma. I ka United States, ua lilo ia i mau mea maikaʻi loa e pili ana i ka lipid-hoʻokuʻu i ka mākeke.

ʻO nā waiwai Pharmacological

ʻO nā PPAR he mau ʻāpana nukle e hoʻolaʻa ʻia e nā kūlohelohe kūlohelohe a kūlohelohe paha, a hoʻonui pū paha i ka hōʻaha ʻana i ka hōʻike o kekahi mau ʻano gen. Aia nā PPA alpha, beta a me nā mea hoʻokipa gamma. Kokoke āpau i nā fibrates e hoʻopili pono ai i nā alpha receptors.

ʻO nā hopena nui o ka lāʻau lapaʻau:

• Mālama i ka hōʻike o apolipoprotein C3 (APOC3), a ke pale aku nei i ka lipoprotein lipase kuleana no ka hydrolysis o intravascular triglycerides (TG). Hoʻonui ka PPAR-alpha i ka hana o ka lipoprotein lipase, e hōʻemi ana i ka neʻe o ka triglycerides i ke koko
• Hoʻonui i ka synthes o APOA1, APOA2 a no laila HDL
• I ka wā o ka hoʻokolohua ʻana i mālama ʻia me ka fenofibrate, ua hōʻemi ʻia ka nui o ke koko ma waena o 20 a 25%, a hoʻonui ʻia ka HDL mai 10 a 30%
• Hoʻemi i ka hōʻike o endothelin-1, kahi vasoconstrictor mana. Eia kekahi, me kēia hana, hoʻoneʻe ka fibrates i ka hōʻike o nā cytokines, ʻoi aku hoʻi i ka IL-1 a me IL-6, no laila, loaʻa kahi hopena anti-inflammatory. Ua ʻike ʻia kekahi me ka hoʻohana ʻana i ka PPAR-alpha, hiki i kekahi mau fibrates ke hōʻemi i ka hōʻike o fibrinogen, no laila hiki iā lākou ke loaʻa kahi hopena antithrombotic.
• Hoʻonui i ka mea huna o ka cholesterol e ka bile, i hiki ke hāʻawi i ka lithogenesis.

Loaʻa ka hoʻokūkū plasma kiʻekiʻe (Cmax) i nā hola 2-4 ma hope o ka lawelawe waha. Hoʻemi nui ka Bioavailability inā lawe ʻia ka lāʻau me ka meaʻai. Ma hope o ka lawelawe waha, ua hoʻopili koke ʻia ka fenofibrate e nā esterases i loko o ka metabolite ikaika - ka hoʻohuihui fenofibric. Ua hui pū ka waikawa Fenofibric me ka plasmain albumin (ʻoi aku ma mua o 98%). ʻAʻole i loaʻa ka fenofibrate i hoʻololi ʻia ma ka plasma. ʻAʻole pono ka lāʻau i kahi papa hana no ka cytochrome P450. ʻAʻole pili ke lāʻau lapaʻau i ka ʻaila mikrosomal hepatic.

Hoʻokuʻu ʻia ka lāʻau mai ke kino ʻoi aku me ka urine. Ua aneane hoʻopau ʻia ka huahana holoʻokoʻa i hoʻokahi pule. Hoʻokuʻu pinepine ʻia ka Fenofibrate ma ke ʻano o ka waikawa fenofibric a me kahi derivative o glucuroconjugate. I nā poʻe maʻi maʻi, ʻaʻole i loli ka hoʻomaʻemaʻe ʻana o ka waila fenofibric. ʻO nā haʻawina ʻo Pharmacokinetic ma hope o hoʻokahi pākaha a me ka hoʻomau mau ʻana ke hōʻike nei i ka nele o ka hōʻuluʻulu ʻana. ʻAʻole hoʻopau i ka waikawa Fenofibric e nā kaʻina dialysis. ʻO ka hapalua hapalua he 20 mau hola.

Nā hōʻailona no ka hoʻohana ʻana

ʻO ke kumukūʻai kumukūʻai o Fenofibrate he 800 mau rubles Lūkini.

Hoʻohana ʻia ka Fenofibrate i ka hoʻohui i nā meaʻai a i ʻole nā ​​lāʻau lapaʻau ʻē aʻe (e like me ka hana ʻana, ka nui o ka kaumaha) i ka mālama ʻana o ka ʻano II, III, IV a me V hyperlipidemia. Hoʻohana ʻia ʻo Fenofibrate e like me ka lāʻau kūʻai lua-lua. Hiki ke hoʻohana ʻia ka lāʻau lapaʻau ke nānā ʻia ka nānā nui o ka lipids ma ke koko. Pono ho‘ohana hou ia i mea ʻē inā ʻaʻole hana iki nā mea ikaika mai ka statin pūʻulu a i ʻole e contraindicated.

I nā noiʻi, hoʻemi ʻia ka mālama fenofibrate i ka pinepine o ka hōʻeha ʻana o ka naʻau ma ka maʻi puʻuwai. Eia naʻe, ʻaʻole i hoʻokūpaʻa ʻia i ka hopena o ka lāʻau i ka hoʻomohala ʻana o nā maʻi cardiovascular.

Nā ʻōkuhi no ka hoʻohana

Wahi a nā kuhikuhi, lawe maʻamau ka fenofibrate i ka lā hoʻokahi. Hoʻomoe iki ka meaʻai o ka meaʻai i ka bioavailability o ka lāʻau. Manaʻo ʻia e inu i ka papa i lawe ʻia me ka wai.

ʻAʻole hoʻohana ʻia i ka wā hāpai a me ka umauma, no ka mea, e like me nā ʻōlelo i hoʻohana ʻia, he hopena teratogenic ka lāʻau.

Nāʻano, nā hopena pili, ka make nui, ka pili o ka lāʻau

ʻO ka Fenofibrate ka hoʻohalike i ka hihia o ka hypersensitivity, nephropathy, ka nele ʻana o ka ate, ka maʻi hepatic maʻi, nā maʻi o ka gallbladder, mua o ka photoallergic a i ʻole phototoxic hopena. I ka mea ʻokoʻa o ka photosensitivity ʻikepili (pane phototoxic) me ka ʻulaʻula, hōʻula, hōʻula a me ka ʻūhā, pono e hoʻihoʻi ʻia ka mea kaha.

Hoʻomaopopo ʻia e hōʻike koke ʻoe i kāu kauka i ka ʻeha, nāwaliwali, a me nā māhuahua o ka naʻau. Pono nā wahine o ka hānau keiki ʻana e mālama pono i ka contraception maikaʻi i ka wā mālama.

Hoʻopilikia ka Fenofibrate i ka hana a me ka pēpē o ka gastrointestinal, hoʻonui i nā enzyme o ka ate, ʻo ka ʻike ʻana o ka homocysteine. Hoʻokumu pū kekahi i ka ʻāʻī o ka naʻau, kahi hāpū maʻi alanui, ka papaʻa, a hoʻāla i nā pae kinase kinase. Ua hōʻike ʻia nā noiʻi hauoli e hiki i ka lāʻau lapaʻau ke hana i kahi kaumaha koʻikoʻi nui me ka hoʻohana lōʻihi.

Hiki i nā pilina o nā lāʻau me nā anticoagulants waha, cyclosporine, nā mea hepatotoxic a me nā mea koho monoamine oxidase. ʻO Fenofibrate kahi mea paʻa i kekahi isoforms cytochrome P450.

ʻO nā mea hui nui o Fenofibrate: Fenofibrate Canon a me Tricor.

Canon Fenofibrat

Mea hana - Canonfarm Production CJSC (Rū Kūlana Russian)

Kūʻai - mai 820 mau rubles

Kuhi - kiʻi ʻoniʻoni aahu ʻia e hoʻohana ʻia no ka mālama ʻana i nā lipids koko kiʻekiʻe

NOHO - hōʻemi i ka pane ʻana o nā lipoproteins hoʻohaʻahaʻa haʻahaʻa a hoʻonui, hoʻonui i ka HDL a loaʻa kahi hopena antithrombotic i nā dosis therapeutic.

Cons - ke kumu ʻana i ka momona, ka ʻeha, ke kaumaha, ka ʻōpū o ka ʻōpū, ka maʻi hepatitis a me ka hana ʻole o ke aʻe

Mea hana - Recifarm Fontaine (Farani)

Kūʻai - mai 1200 mau rubles

Ka wehewehe - kiʻi ʻoniʻoni polike i loaʻa ka fenofibrate micronized, ka mea e hoʻohana ai e mālama i nā koikoi kiʻekiʻe o ka cholesterol a me ka triglycerides i loko o ke koko.

NOHO - hōʻemi i ka paʻa o LDL, VLDL, fibrinogen a hoʻonui i ka HDL. Hoʻomaka ka ʻike o nā hōʻailona o ka mākaukau a me ka uric acid i ke kahe koko.

Cons - kumu nā dyspepsia, hoʻonui i nā Enzim eno, jaundice, gallstones, rhabdomyolysis, erectile dysfunction a me ka cephalgia koʻikoʻi.

E hoʻokuʻu i nā palapala a me ka ʻano

ʻO ka lāʻau lapaʻau i hana i ke ʻano o nā papa i hōʻike ʻia nā membrane. Aia i kēlā me kēia papa o ka lāʻau lapaʻau ka 145, 160 a i ʻole 180 mg o ka micronized fenofibrate i ke ʻano o nanoparticles. Hoʻohana ʻia nā mea hoʻohui aku:

• waiū waiū
• mikuleka
• crospovidone
• haniailahion,
• dehydrogenated sililikina kāpili colloidal,
• huehue
• laulea laulea
• paʻahau magnesium.

ʻO ka lāʻau lapaʻau i hana i ke ʻano o nā papa i hōʻike ʻia nā membrane.

ʻO ka waho waho o ka talc, xanthan gum, titanium dioxide, polyvinyl alkohol a soya lecithin. Loaʻa nā papa keʻokeʻo i kahi ʻano elongated me ke kahakaha ma nā ʻaoʻao ʻelua o ke ʻano dosage, e hōʻike ana i ka leka mua o ka mea a me ke ʻano.

Nā hana hana i ka hana

ʻO nā papa Fenofibrate e pili ana i ka hui o nā mea maʻi hypoglycemic a he kahi kumu o ka waikawa fibroic. Hiki i kēia mea kūpono ke hana i ke kiʻekiʻe o lipids i ke kino.

ʻO nā waiwai Pharmacological ma muli o ka hoʻonaninani ʻo RAPP-alpha (kahi ʻāpihi i hoʻāla ʻia e kahi proliferator peroxisis). Ma muli o ka hopena hoʻonāukiuki, hoʻonui ke kaʻina metabolic o ka momona hōʻokiʻoki a me ka hoʻopiʻi ʻana o ka lipoproteins plasma-low low (LDL). Hoʻohui ʻia ka hoʻohua ʻana o ka apoproteins AI a me AH, no laila ke hoʻonui ʻia nei ka pae kiʻekiʻe o ka lipoproteins kiʻekiʻe (HDL) ma o 10-30% a hana ʻia ka lipoprotein lipase.

Ma muli o ka hoʻihoʻi hou ʻana o ka momona metabolism i kahi hihia i hikiʻole i ka hoʻokumu ʻana o VLDL, hoʻopiʻi ka pūnaehana fenofibrate i ka excretion o LDL, e hōʻemi ana i ka nui o nā palaka o nā lipoproteins haʻahaʻa haʻahaʻa me ka liʻiliʻi.

Hoʻonui ka nui o LDL i nā maʻi ma ka hopena me ka hoʻomohala ʻana i ka maʻi naʻau coronary.

Kōkua ka lāʻau lapaʻau e hōʻemi i ka cholesterol ma o 20-25% a me nā triglycerides e 40-55%. I mua o ka hypercholesterolemia, e emi iho ana ka pae o ka kolamu e pili ana i ka LDL e pili ana i ka 35%, aʻo ka hāhai ka hyperuricemia a me ka atherosclerosis i ka hoʻomohala ʻana i ka waikika uric i ke koko ma ka 25%.

Lapaʻau lāʻau

Ke lawe waha ʻia, hoʻohuihui ʻia ka mea hoʻohuihui o ka micronized i loko o ka wahi e pili ana i ka ʻōpū liʻiliʻi e hoʻohana ana i nā microvilli, mai kahi e komo ai ka pili o nā kīʻaha koko. Ke komo nei i ka ʻāpana o ka ʻawa, hiki ke hoʻoneʻe koke i ka mea hana a ka fenofibroic acid e ka hydrolysis me nā esterases. Hiki i ka huahana decay ke kiʻekiʻe loa o ka pae plasma i loko o 2-4 mau hola. ʻO ka ʻai ʻana ma ka helu o ka ʻimi ʻana a me ka bioavailability o ka pā ʻana ma ka nanoparticles.

Ke komo nei i ka ʻāpana o ka ʻawa, hiki ke hoʻoneʻe koke i ka mea hana a ka fenofibroic acid e ka hydrolysis me nā esterases.

I ke kahe koko, e hoʻopili ai ka mea hana paʻa i ka albumin plasma e 99%. ʻAʻole ke ola i ka lāʻau lapaʻau i ka hana hoʻōla o nā mikrosomal. ʻO ka hapalua hapalua ke ola a 20 mau hola. Ma ke ʻano o nā hoʻokolohua hoʻomaʻemaʻe, ʻaʻohe mau hihia o ka cumulation ʻelua me ka ʻokahi hoʻokahi a i ʻole me ka manawa lōʻihi o ka hāʻawi ʻana i ka lāʻau. ʻAʻohe huakino ka Hemodialysis. Hoʻopau ʻia ka lāʻau lapaʻau ma ke ʻano o ka waikawa fenofibroic i loko o 6 mau lā ma o ka urinary system.

Nā Hoʻohui

ʻAʻole i kuhikuhi ʻia ka lāʻau lapaʻau ma muli o nā contraindications paʻa:

• hypersensitivity i ka fenofibrate a me nā mea waiwai'ē aʻe o ka lāʻau,
• maʻi ate
• hooulu pilikia,
• hoʻoilina galactosemia me ka fructosemia, nele o ka lactase a me ka sucrose, nā huina hoʻohuihui a me ka lawe ʻana o ka galactose,
• ka mōʻaukala o nā ʻōiwi ʻōiwi.
• ka hoʻowali ʻana i ka mālamalama i ka wā e mālama ʻia ai me Ketoprofen a i ʻole nā ​​fibrates ʻē aʻe.
• kaʻina pili i loko o ka pīpī.

ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no ka galactosemia hoʻoilina.
ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no ka maʻi o ka naʻau.
ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no ka fructosemia hoʻoilina.
ʻAʻole i kuhikuhi ʻia ka lāʻau lapaʻau no ka hana ʻoi loa.
ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no nā maʻi ʻōiwi hoʻoili i ka mōʻaukala.
ʻAʻole i kuhikuhi ʻia ka lāʻau lapaʻau no nā kaʻina pili i loko o ka pīpī.

ʻO nā poʻe me ka hopena anaphylactoid i ka pīni a me ka pīkī pīpī ʻaʻole pono e lawe i ka lāʻau.

Nā lāʻau lapaʻau, INN, the scope

No ka Fenofibrate i kahi hui kūikawā - lipid-hoʻemi i nā lāʻau i hana ʻia ma ke kumu o ka waila fibroic. Hiki i kēia mau lāʻau ke hōʻemi i ka maikaʻi o ka kolamu o ka "maikaʻi" i ke koko a hōʻemi i ka pae o ka triglycerides.

Hoʻohana ʻia ka lāʻau lapaʻau e hōʻemi i ka hoʻoulu ʻana o nā lipids, ka hōʻiliʻili nui o ka mea e hoʻopilikia kino i ke olakino kanaka. Hāʻawi pinepine ʻia no nā maʻi me ka maʻi mellitus, me nā ala o ka puʻuwai a me nā kīʻaha koko (no ka laʻana, ischemia cardiac, atherosclerosis) e hoʻoponopono i ke kiʻekiʻe o lipids.

ʻO Fenofibrate ka INN, ʻo ia ka mea e komo ai i ka lāʻau lapaʻau a hoʻoholo i ka hana o kāna hana ma ke kino.

Hoʻolaha ka puka, uku ma Rusia

Hoʻokuʻu ʻia ka lāʻau lapaʻau ma ke ʻano o nā papa i loaʻa ke keʻokeʻo, he ʻōpū ʻokoʻa a me ka kaula hoʻokaʻawale. Aia i kēlā me kēia papa āpau ka 145 mg o nā mea ikaika. Hoʻopili ʻia lākou ma nā palaka plastik no 7, 10 a i ʻole 15 mau ʻāpana. I ka huina, ma loko o ka pahu pahu pahu aia mai 10 a 100 papa papa.

Kau ʻia ke kumukūʻai ma ka helu o nā papa i loko o ka pulu, e like me ka wahi e kūʻai ai i ka lāʻau lapaʻau. Ua hōʻike ʻia ma ka papa ʻaina nā kumukūʻai no kahi pā 30 mau papa o 145 mg i loko o nā haleʻai o nā kūlanakauhale nui o Rūsia ma ka papa ʻaina.

ʻO nā kumukūʻai kūʻai kūpono loa e hāʻawi ʻia ana e nā lāʻau kūʻai pūnaewele. Ma laila hiki iā ʻoe ke kauoha pololei i ka lawe ʻana i kou home i kou home.

ʻO nā mea hoʻohui

ʻO ka māhele nui o ka lāʻau lapaʻau ka fenofibrate. Ua kapa ʻia ʻo ia no ka huaʻai a nā fibroic acid (fibrates). Aia ma kahi papa he 145 mg o kēia ʻano. Eia kekahi, ʻo ka māhele o ka lāʻau lapaʻau ka mea o ia mau mea - selulose, magnesium stearate, povidone, mannitol, starch, silicon dioxide. He hana kōkua pū kekahi iā lākou.

Nā Pāʻohana Lapaʻau

Hiki i ka Fenofibrate ke hoʻopili i nā mea kikowaena alpha kūikawā (RAPP). Ke alakaʻi nei kēia i ka lipolysis hoʻonui a me ka wehe ʻana i nā lipoproteins hoʻohaʻahaʻa maikaʻi mai ke koko, hiki ke hōʻiliʻili a waiho i luna o nā pā o ke koko, e hoʻowalewale i nā hopena maikaʻi ʻole. I kēia hihia, ʻike ʻia nā hopena like ʻole:

• hoʻemi i ka triglycerides a me ka cholesterol maikaʻiʻole,
• ka hoʻemi ʻana i ka nui o nā waika uric (hopena uricosuric),

ka hoʻohanohano ʻana o ka platelet aggregation (pale ʻana i ka thrombosis),

Ma hope o ka lawelawe waha, ua paʻa piha ka lāʻau i ka gastrointestinal tract ma hope o 4 mau hola. Inā hele ʻole ia ka ʻōnaehana, a laila lilo ka manaʻo i ke koko o ka hana a mau. Hoʻopiliʻo Fenofibrate i kahi kokoke i nā protein koko.

Ma ke kaʻina o kāna kaʻina hana hamofibroic acid i hoʻokumu ʻia. ʻAʻole ia e komo i loko o ka ʻaina mikrosomal. Hoʻopuka ka excretion i nā keiki. Loaʻa ka hapalua-ola i nā hola 20 ma hope o ka hoʻokele ʻana. E lilo ia i 6 mau lā e hoʻopau piha i nā huahana o nā metabolites fenoforbit.

Nā hōʻailona a me nā palena

Hoʻomaopopo ʻia ka lāʻau lapaʻau e hōʻemi i ka pae o ka triglycerides a me ka haʻahaʻa haʻahaʻa haʻahaʻa me nā pathologies:

Hoʻopili ʻia. Hoʻōla pinepine ia me nā maʻi:

• maʻi mellitus maʻiʻi
• ischemia
• nā atherosclerotic kaʻina ma ka peripheral a carotid arteries,
• ʻōpū ʻōpū o ka ʻōpū o ka ʻōpū,
• i nā palapala ʻē aʻe ʻē aʻe. Hoʻohana pinepine ʻia ka lāʻau lapaʻau i ka hui pū me nā statins i mea e hōʻemi ai i ka triglycerides a hoʻonui i ka HDL (cholesterol maikaʻi).

ʻO ka wā lōʻihi a me ka regimen lapaʻau e hoʻoholo ʻia e ke kauka hele mai. Ma mua o ka hoʻoluhi ʻana i kahi lāʻau lapaʻau, pono ʻoe e hōʻoia e loaʻa i ka mea maʻi i nā contraindications e like:

• ka ahalike kanaka ʻole i nā ʻāpana i hana i ka lāʻau lapaʻau,
• pilikia hōʻeha loa,
• hypersensitivity e pili i nā fibrates a me Ketoprofen,
• mea ʻōpiopio,
• ka maʻi a me ka maʻi pancreatitis (ʻoi aku ma mua o ka mea i lawe ʻia e ka hypertriglyceridemia),
• keiki a me ʻōpio,
• wā GW,
• hapai
• hana lōkū āpau (cirrhosis).

ʻAʻole ia i hoʻāʻo ʻia ka lāʻau lapaʻau i nā keiki ʻōpio, nā wahine hāpai, a me nā makuahine hānai. No laila, ʻaʻole i ʻike ʻia ka pilikia o nā pōpilikia o ia mau lehulehu. No ka mea hiki iā fenofibrate ke komo i loko o ka plasenta a i loko o ka waiū waiū, ʻaʻole ia he mea pono ke hoʻohana ʻia i ʻole e hōʻeha i ka pēpē.

Me ka makaʻala nui loa a ma lalo o ka mākaʻi o ke kauka, hoʻohana ʻia ka lāʻau lapaʻau no ka hypothyroidism, renal pathologies, penei hoʻi no ka mālama ʻana i nā mea maʻi maʻi a me nā poʻe i hōʻino maikaʻi i ka waiʻona.

Ino no ka hoʻohana

He mea nui e lawe pololei me ka fenofibrate. E kōkua kēia i nā ʻōkuhi no ka hoʻohana ʻana, a e ʻae nei:

1. E lawe i nā papa i loko me ka ʻole e kāloi me ka wai.
2. ʻĀ ʻia ka lāʻau lapaʻau i ka manawa hoʻokahi i ka lā, e hoʻohui pū i kona hakina me ka ʻai o ka meaʻai (no laila e ʻoi aku ka maikaʻi).
3. ʻO ka halaʻana o ka lāʻau no nā ala like ʻole he 145 mg i kēlā me kēia lā. ʻAʻole pono nā poʻe maʻi i ka hoʻoponopono hoʻoponopono ʻia.

Pono ka lōʻihi o Fenofibrate. I kēia hihia, pono e mālama pono i ka ʻai hypocholesterol.

Ma hope o kekahi manawa (e pili ana i 3 mau mahina ma hope o ka hoʻomaka ʻana o ka hōʻola), pono e nānā ʻia ke koko o ka mea maʻi e ʻike i nā ʻanoʻano maikaʻi ʻana. Inā ʻaʻole mālama ʻia kēia, pono ʻoe e hoʻoponopono i ka iki a hoʻololi paha i ka hoʻoponopono lāʻau lapaʻau.

Hoʻohui nūhou

Hiki i ka lāʻau lapaʻau ke hoʻohui pū me ka mamao loa i nā lāʻau lapaʻau. Eia kekahi mau hiʻohiʻona o kona pilina me nā lāʻau lapaʻau ʻē aʻe:

1. Me ka hoʻokolohua kūwaho me nā anticoagulants, hoʻonui ʻia ko lākou hopena. Hiki i kēia i ke koko. Inā makemake ʻoe e hoʻohana iā lākou i ka manawa like, a laila e hōʻemi ʻia ka nui o nā anticoagulants e 3 mau manawa.
2. Fenofibrate me ka cyclosporine, i ka wā e hui pū ai, e hoʻonāukiuki i ka ʻeha o ka hana o ke akepaʻa.
3. ʻO ka hoʻohana pono ʻana me nā fibrates e hoʻonui i ka hopena o ka hoʻomohala ʻana i ka hana hōʻino i ka fibers uaua.

Nā ʻōlelo kikoʻī

Pono ia e aʻo i nā ʻōlelo kūikawā ma mua o ka hoʻohana ʻana i ka lāʻau lapaʻau. I waena o lākou:

1. ʻAʻole maikaʻi ka lāʻau lapaʻau inā ʻaʻole ʻoe e hōʻalo i nā maʻi e hoʻonāukiuki i ka nui o nā pae lipid.
2. Ke lawe nei i ka lāʻau lapaʻau, pono ʻoe e hahai i kahi ʻai me kahiʻu kolamu liʻiliʻi.
3. Hiki ke loiloi ka hopena o ka mālama ʻia e nā hopena o kahi hōʻike koko no ke kiko o ka cholesterol piha, LDL, triglycerides.
4. Inā lawe ka mea maʻi i nā lāʻau lapaʻau hormonal, no laila e ʻike ʻoe inā ʻaʻole ka hopena o ka hoʻonui ʻana o ka pae lipid.
5. I ka makahiki mua o ka lawe ʻana i ka lāʻau lapaʻau, ua hōʻike ʻia e nānā i ke kiʻekiʻe o ka transaminases hepatic (ALT a me AST).

Nā Kūlana ALT a me AST

Hiki i nā hana kūʻokoʻa ke hoʻonui i ka pono o ka lāʻau lapaʻau, me ka pale ʻana i ka hiki ke hoʻomohala ʻia o nā hopena maikaʻi ʻole a me nā hōʻahewa.

Nā hopena hopena, nā ʻōmole overdose

Ua lawa nā hopena ʻaoʻao o ka lāʻau lapaʻau. Kū pinepine lākou ma muli o ka hoʻohana pono ʻole. I kēia hihia, ʻike ʻia nā maʻi:

• pilikia kūwili, i hōʻike ʻia e ka mualele, ka luaʻi, ka ʻōpū, ka ʻeha o ka ʻōpū, ke ʻī ʻana,
• lōkohu
• ka hoʻonohonoho ʻana o nā pōhaku i nā hua bile,
• ka hoʻomohala ʻana i ka hepatitis (i hōʻike ʻia e ka maʻi lahilahi, ka ʻeha ʻeha),
• ʻōpū, nāwaliwali o ka naʻau a me ka ʻeha.
• hoʻonui i nā keʻena koko keʻokeʻo a me ka hemoglobin,
• poʻomanaʻo
• ka hōʻino ʻana i ka hana moekolohe,
• thromboembolism, leukocytosis,
• huehae huehal i pau
• hana maʻi i loko o nā ʻala
• lauoho lauoho
• nā hopena kūlohelohe i ka ʻili i ke ʻano o ka ʻulaʻula, ka ʻeha, ka rashes, urticaria,
• photophobia.

Loaʻa pinepine loa ka overdose. I kēia hihia, pono e lawe ʻia ka mea maʻi i kahi lāʻau lapaʻau. Hāpai lākou i ka lapaʻau hōʻailona. ʻAʻole hiki ke haʻalele i ka lāʻau lapaʻau me ka hemodialysis.

ʻO nā ʻano like

ʻO Fenofibrate e pili ana i nā mea hana hypoglycemic. Loaʻa kona mau kikowaena kikoʻī i ka waiwai like. ʻO ka mea kaulana loa o lākou:

1. ʻO ka Tricor he kumukūʻai a nani loa ia, akā naʻe ʻo ka lāʻau lapaʻau kiʻekiʻe mai Farani.
2. ʻO Lipantil kahi huahana Farani e loaʻa ana i ka 200 mg o ka fenofibrate i 1 papa.
3. ʻO ka Exlip kahi kahi lāʻau lapaʻau e kākoʻo i kahi Turkish he 250 mg o fenofibrate.

Aia kekahi mau lāʻau i nā meaʻokoʻa'ē aʻe, akā loaʻa kahi hopena like. I waena o lākou:

1. Atorvacor. ʻO ka lālani ke loaʻa i ka atorvastatin kahe a me ka mea o ka pale o HMG-CoA reductase. Hoʻohana ʻia ia no ka hyperlipidemia.
2. Livostor. Loaʻa ka huahana me ka atorvastatin. He lāʻau maʻalahi ia i ka lāʻau e hoʻohaʻahaʻa i ka kolamu koko.
3. Tulip. Hana ʻia e ka hui lāʻau lāʻau ʻo Sandoz ma Polani. Hoʻohana ʻia ʻo Atorvastatin ma ke ʻano he mea ikaika.

Hoʻohana ʻia kēlā mau kālā no ka hakakā ʻana no ka fenofibrate. E kuhikuhi i kekahi a i ʻole kekahi analogue hiki ke kauka i ke kauka.

Hōʻikeʻike i nā kauka a me nā maʻi

I mea e loiloi ai i ka pono o ka lāʻau lapaʻau, pono ia e ʻike i nā mea a nā kauka a me kā lākou mau maʻi e ʻōlelo ai e pili ana iā Fenofibrate. Eia kekahi mau ʻike maoli:

ʻO ka lāʻau Fenofibrate he hopena kūpono no ka mālamaʻana i ka hyperlipidemia. Aia kona pōmaikaʻi ma ka hōʻiliʻili ʻana o ka hana ikaika i loko o ke koko, e alakaʻi ai i ka hopena mau loa - he ʻemi i loko o ka LDL a me ka triglycerides.

Pehea e lawe ai iā Fenofibrate

Lawe ʻia nā papa me ke kā ʻole ʻana. Pono ka poʻe maʻi maʻi e lawe i ka 145 mg o ka lāʻau i ka lā. Ke hoʻololi nei mai kahi kaʻa o 165, 180 mg i kahi lā i kēlā me kēia lā o 145 mg, ʻaʻole pono ka hoʻoponopono hou ʻana o ke ʻano maʻamau i kēlā me kēia lā.

ʻO ka lāʻau e kauoha ʻia e lawe ʻia no ka lōʻihi o ke ʻano o ke ʻano o ka lāʻau lapaʻau kūpono. Pono ka hoʻomaʻamaʻa ʻana o ka hoʻomaʻamaʻa ʻana i nā kauka i hele mai e pili ana i ka ʻike serum lipid.

Lawe ʻia nā papa me ke kā ʻole ʻana.

Pūnaehana pīhoihoi waena

Hiki i kahi maʻi Erectile a me ke poʻo hiki ke hōʻeha me nā hopena i hoʻopau ʻia i ka pehu.

Me nā hewa hewa o ka lāʻau lapaʻau, hiki ke hopena i kahi hopena ma ke ʻano o nā hopu.
Me ka hala hewa o ka lāʻau, hiki ke hopena i ka hopena ma ke ʻano o ka ʻeha o ka naʻau.
Me ka hala hewa o ka lāʻau, hiki i kahi hopena ʻaoʻao ke ʻano o ke kahiki ma ka ʻili.
Me ke hala hewa o ka lāʻau, hiki i ka hopena ʻaoʻao ke ʻano o ka piʻi ʻana o ka neʻe ʻana o nā pona o nā keʻokeʻo ke koko i ke koko.
Me ka hala hewa o ka lāʻau, hiki ke hopena i ka hopena ma ke ʻano o ka huehue.
Me ka hewa hewa o ka lāʻau lapaʻau, ʻike ʻia kahi hopena ma ke ʻano o ka luaʻi.
Me ka hala hewa o ka lāʻau, hiki i kahi hopena ʻaoʻao ke ʻano o ka lauoho lauoho.

Mai ka pūnaehana genitourinary

ʻAʻole i loli ka hewa hewa i ka hana o nā papa urinary.

I ka nui o nā manawa, ua ʻāʻī ka ʻili, ka photosensitivity (ʻike i ka mālamalama), ʻeha a hives paha ke ʻano o ka hōʻeha a me ke kaumaha. I nā hihia lohi, ʻike ʻia ka lauoho, ka hiʻohiʻona o ka erythema, blisters a he nodules a me nā hono e hoʻopili ai ma lalo o ka hopena o ka radiation ultraviolet.

Hoʻopilikia i ka hiki ke mālama i nā mīkini

ʻAʻole ka hopena o ka lawe ʻana i ka Fenofibrate i ka neʻe ʻana, hoʻonaʻauao kino a me ka naʻau, no laila, i ka manawa o ke ʻano lipid-e hoʻohiolo ana, kaʻa ʻana i ke kaʻa a hana pū me nā mea paʻakikī.

I ka wā e lawe ai i ka lāʻau lapaʻau, ʻae ʻia ka hoʻokele kaʻa a me ka hana me nā mea paʻakikī.

Hoʻohana i ka wā hāpai a me ka lactation

Ma nā haʻawina loiloi i nā holoholona, ​​ʻaʻohe hopena teratogenic. Ma nā noi preclinical, ua hoʻopaʻa ʻia ka pehu i ka kino o ka makuahine a me ka pilikia i ka maʻi fetus, no laila, lawe wale ʻia ka lāʻau inā he hopena maikaʻi loa no ka wahine hāpai i ka nui o ka hōʻemi o ka anomalies intrauterine i ke keiki.

Hoʻopau ke kūpeʻe ʻana i ka wā mālama.

Hoʻonohonoho ʻana i ka Fenofibrate i nā Keiki

ʻAʻole ʻōlelo ia ka lāʻau no nā keiki a me nā ʻōpio ma lalo o ka 18 mau makahiki ma muli o ka nele o ka ʻike i ka hopena o Fenofibrate ma ka ulu a me ka hoʻolālā ʻana o ke kino.

ʻAʻole mālama ʻia ka lāʻau lapaʻau no nā keiki a me nā ʻōpio i lalo o 18 makahiki o kona mau makahiki.
Hoʻopiliʻia ka wā hoʻomaha i ka wā e mālama ai me ka lāʻau lapaʻau.
ʻO ka lawe ʻana i ka lāʻau lapaʻau i ka wā hapai e lawe ʻia wale nō inā he hopena maikaʻi paha no ka wahine hāpai i ka hopena o ka hōʻeha o ka intrauterine abnormalities i loko o ke keiki.

Ke keu

ʻAʻole i loaʻa i nā hihia o ka overdose ma muli o ka pono o ka lāʻau lapaʻau. ʻAʻohe mea kikoʻī i kēlā me kēia kūlike. No laila, inā he mea maʻi me ka pākahi hoʻokahi o ke kiʻekiʻe kiʻekiʻe e hoʻomaka i ka maʻi, hōʻiliʻili a i ʻole nā ​​hopena ʻokoʻa, pono ia e ʻimi i ke kōkua olakino. Me ka hoʻokipa hoʻomaha, hoʻopau ʻia nā hōʻike hōʻailona o ka overdose.

Hoʻopili pū me nā lāʻau ʻē aʻe

Ke hoʻohui i ka fenofibrate me anticoagulants no ka hoʻokūkū waha, hoʻonui i ka pono o ka lāʻau lapaʻau i ka nīnau. Me kēia hui, ulu ka hopena o ke koko ma muli o ka hemo o ka anticoagulant mai nā protein koko plasma.

Me ka hoʻohana pākuʻina o ka blockers redmase HMG-CoA, ka piʻi ʻana o ka hopena o ka hopena ʻalopona i hōʻea nā mea momona, no laila e loaʻa ka mea maʻi i nā statins, pono e hoʻopau i ka lāʻau.

Ka hāʻawi ʻana o Cyclosporine i ka nāi ʻana o nā keiki, no laila ke lawe ʻana iā Fenofibrate, pono ʻoe e nānā pinepine i ke ʻano o ke kino. Inā pono, ke hoʻopau ʻia ka hoʻokele ʻana o ka lāʻau hypolipidemic.

Hoʻolaha ka waipuna

I ka wā o ka mālama ʻana me Fenofibrate, ua pāpā ʻia ʻole ia e inu i ka ʻawa. Hoʻopaliwali ʻo Ethyl alkohol i ka hopena therapeutic o ka lāʻau, hoʻomaikaʻi i ka hopena o nā mea laʻala i nā pona o ke ake, ke kahua kūlohelohe a me ke kahe koko.

Kūpono o nā lāʻau lapaʻau me nā ʻano hana like me nā hana like:

• Tricor
• Atorvacor
• Lipantil
• Kaleikano,
• Canon Fenofibrate papa,
• Livostor
• Exlip,
• Trilipix.

Ke huli nei i kahi lāʻau lapaʻau e hana hou ma hope o ke kūkā ʻana o ke kauka.

Kaukaʻi aʻoaʻo Tricor Lipantil 200 M aʻo ia i ka ʻōlelo aʻo Phenofibrate CANON

Ke waiho nei i nā kūlana no ka lāʻau lapaʻau

Manaʻo ʻia e mālama i ka lāʻau lapaʻau i nā mahana a hiki i + 25 ° C ma kahi maloʻo, kahi mamao aku mai ka lā.

Manaʻo ʻia e mālama i ka lāʻau lapaʻau i nā mahana a hiki i + 25 ° C ma kahi maloʻo, kahi mamao aku mai ka lā.

Hōʻikeʻike Fenofibrate

Aia nā ʻōlelo hoihoi a me nā mea maʻi.

Olga Zhikhareva, cardiologist, Moscow

Maikaʻi i ka hakakā me nā triglycerides kiʻekiʻe. Manaʻo wau e hoʻohana no nā ʻano IIa, IIb, III a me IV hyperlipoproteinemia. Ma ka hana lapaʻau, kuhikuhi wau i ka lōʻihi o ka hoʻokele a me ka dosage ma kēlā me kēia kanaka hoʻokahi. ʻAʻole i ʻike ʻia nā hopena ʻaoʻao. ʻAʻole kahi hopena kūpono i ka hoʻohaʻahaʻa i ka cholesterol.

Afanasy Prokhorov, kahu hānai, Yekaterinburg

Me ka momona nui a me ka kolamu kiʻekiʻe, kōkua maikaʻi ka fenofibroic. Nui aʻe me ka hana haʻahaʻa o ka hoʻomaʻamaʻa ʻana a me ka ʻai. I ka wā hana, hoʻolaha wau i ka haʻalele ʻana i nā hana ʻino a hahai ikaika i nā ʻōlelo a ke kauka e hoʻonui i ka hana pono.

Nazar Dmitriev, 34 makahiki, Magnitogorsk

ʻO ka hopena maikaʻi. Palapala 5.4. Me ka hoʻohana maʻamau o Fenofibrate, ua hōʻemi ke kiʻekiʻe o ka momona i ka 1.32. ʻO ka palena ʻāina he 1.7. ʻAʻole i ʻike ʻia nā hopena hōʻike.

Anton Makaevsky, 29 makahiki, St. Petersburg

Ua lawe ʻo ia i kahi makahiki ma mua o Torvacard ma muli o ka haʻahaʻa o HDL. Ma hope o 4-5 mau noho hoʻokele ʻana, hoʻomaka ka hōʻeha ʻana o ka maʻi me ka hōʻeha ma ka ʻōpū o luna. Ma hope o 8-9 mau mahina, ua hana lākou i kahi hana ʻokiʻoki e wehe i ka maʻi humuhumu. Ua loaʻa nā pōhaku bile a me nā pōhaku hoʻokuʻu. Ma hope o ka hana, ua pau nā mea kaua.

Mikhail Taizhsky, 53 makahiki, Irkutsk

Ua inu ka lāʻau lapaʻau e hoʻoikaika i nā pā vascular, akā ʻaʻole hiki iaʻu ke ʻōlelo e pili ana i ka hana. ʻAʻoleʻike nā ʻōhua. Me ke kōkua o ka lāʻau lapaʻau, hoʻemi ka nui o ka paona ma o ka pololi, akā ua hiʻona nui ka ʻili. Pono ke hana hou. Ua hauʻoli wau i ka hopena.